These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28148635)

  • 1. High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Steinmiller KC; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stuve O; Arnold DL; Wener MH; Georges GE; Wundes A; Kraft GH; Bowen JD
    Neurology; 2017 Feb; 88(9):842-852. PubMed ID: 28148635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.
    Nash RA; Hutton GJ; Racke MK; Popat U; Devine SM; Griffith LM; Muraro PA; Openshaw H; Sayre PH; Stüve O; Arnold DL; Spychala ME; McConville KC; Harris KM; Phippard D; Georges GE; Wundes A; Kraft GH; Bowen JD
    JAMA Neurol; 2015 Feb; 72(2):159-69. PubMed ID: 25546364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain volume change after high-dose immunosuppression and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis.
    Lee H; Nakamura K; Narayanan S; Brown RA; Nash RA; Griffith LM; Steinmiller KC; Devine SM; Hutton GJ; Popat U; Racke MK; Georges GE; Bowen JD; Arnold DL
    Mult Scler Relat Disord; 2021 Sep; 54():103149. PubMed ID: 34284316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study.
    Burt RK; Loh Y; Cohen B; Stefoski D; Balabanov R; Katsamakis G; Oyama Y; Russell EJ; Stern J; Muraro P; Rose J; Testori A; Bucha J; Jovanovic B; Milanetti F; Storek J; Voltarelli JC; Burns WH
    Lancet Neurol; 2009 Mar; 8(3):244-53. PubMed ID: 19186105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis.
    Nash RA; Bowen JD; McSweeney PA; Pavletic SZ; Maravilla KR; Park MS; Storek J; Sullivan KM; Al-Omaishi J; Corboy JR; DiPersio J; Georges GE; Gooley TA; Holmberg LA; LeMaistre CF; Ryan K; Openshaw H; Sunderhaus J; Storb R; Zunt J; Kraft GH
    Blood; 2003 Oct; 102(7):2364-72. PubMed ID: 12763935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis.
    Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF
    J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis.
    Burt RK; Balabanov R; Han X; Sharrack B; Morgan A; Quigley K; Yaung K; Helenowski IB; Jovanovic B; Spahovic D; Arnautovic I; Lee DC; Benefield BC; Futterer S; Oliveira MC; Burman J
    JAMA; 2015 Jan; 313(3):275-84. PubMed ID: 25602998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.
    Burt RK; Balabanov R; Burman J; Sharrack B; Snowden JA; Oliveira MC; Fagius J; Rose J; Nelson F; Barreira AA; Carlson K; Han X; Moraes D; Morgan A; Quigley K; Yaung K; Buckley R; Alldredge C; Clendenan A; Calvario MA; Henry J; Jovanovic B; Helenowski IB
    JAMA; 2019 Jan; 321(2):165-174. PubMed ID: 30644983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes of autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis: physician's and patient's perspectives.
    Shevchenko JL; Kuznetsov AN; Ionova TI; Melnichenko VY; Fedorenko DA; Kurbatova KA; Gorodokin GI; Novik AA
    Ann Hematol; 2015 Jul; 94(7):1149-57. PubMed ID: 25711670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role and place of high-dose immunosuppressive therapy and autologous transplantation of hematopoietic stem cells for autoimmune diseases].
    Makarov SV; Rossiev VA; Mishchenko OV; Kozlov VA; Semagina OV; Alexandrova IY; Grishina GV; Minaev YL
    Ter Arkh; 2016; 88(1):53-59. PubMed ID: 26978610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results.
    Bowen JD; Kraft GH; Wundes A; Guan Q; Maravilla KR; Gooley TA; McSweeney PA; Pavletic SZ; Openshaw H; Storb R; Wener M; McLaughlin BA; Henstorf GR; Nash RA
    Bone Marrow Transplant; 2012 Jul; 47(7):946-51. PubMed ID: 22056644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
    Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
    Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study.
    Curro' D; Vuolo L; Gualandi F; Bacigalupo A; Roccatagliata L; Capello E; Uccelli A; Saccardi R; Sormani MP; Mancardi G
    Mult Scler; 2015 Oct; 21(11):1423-30. PubMed ID: 25583838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis.
    Casanova B; Jarque I; Gascón F; Hernández-Boluda JC; Pérez-Miralles F; de la Rubia J; Alcalá C; Sanz J; Mallada J; Cervelló A; Navarré A; Carcelén-Gadea M; Boscá I; Gil-Perotin S; Solano C; Sanz MA; Coret F
    Neurol Sci; 2017 Jul; 38(7):1213-1221. PubMed ID: 28396953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported changes in the expanded disability status scale score in patients with multiple sclerosis after autologous stem cell transplants: real-world data from a single center.
    Ruiz-Argüelles GJ; Olivares-Gazca JC; Olivares-Gazca M; Leon-Peña AA; Murrieta-Alvarez I; Cantero-Fortiz Y; Gomez-Cruz GB; Ruiz-Argüelles A; Priesca-Marin M; Ruiz-Delgado GJ
    Clin Exp Immunol; 2019 Dec; 198(3):351-358. PubMed ID: 31394007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab for multiple sclerosis.
    Riera R; Porfírio GJ; Torloni MR
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD011203. PubMed ID: 27082500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.
    Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson JE; Isaksson C; Hägglund H; Carlson K; Fagius J
    J Neurol Neurosurg Psychiatry; 2014 Oct; 85(10):1116-21. PubMed ID: 24554104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series.
    Nicholas RS; Rhone EE; Mariottini A; Silber E; Malik O; Singh-Curry V; Turner B; Scalfari A; Ciccarelli O; Sormani MP; Olavarria E; Mehra V; Gabriel I; Kazmi MA; Muraro P;
    Neurology; 2021 Aug; 97(9):e890-e901. PubMed ID: 34253634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.